← Back to Screener
Aktis Oncology, Inc. Common stock (AKTS)
Price$19.48
Growth ScoreB
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-80.97%
Price vs S&P 500 (4W)1.83%
VGM Score55.64
Market Capitalization$1.15B
All Metrics
P/CF (Annual)79.59x
Book Value / Share (Quarterly)$9.48
P/TBV (Annual)0.80x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)147.45%
Price vs S&P 500 (YTD)-16.40%
Gross Margin (TTM)-11.60%
Net Profit Margin (TTM)-843.85%
EPS (TTM)$-1.64
10-Day Avg Trading Volume0.15M
EPS Excl Extra (TTM)$-1.64
Revenue Growth (5Y)86.32%
EPS (Annual)$-1.26
ROI (Annual)-34.03%
Gross Margin (Annual)-11.49%
Net Profit Margin (5Y Avg)-443.97%
Cash / Share (Quarterly)$10.08
Revenue Growth QoQ (YoY)100.43%
ROA (Last FY)-24.06%
Revenue Growth TTM (YoY)49.91%
EBITD / Share (TTM)$-1.89
ROE (5Y Avg)-68.61%
Operating Margin (TTM)-1001.54%
Cash Flow / Share (Annual)$-1.46
P/B Ratio2.27x
P/B Ratio (Quarterly)1.89x
Net Income / Employee (Annual)$-806,700
EPS Growth QoQ (YoY)16.66%
EPS Incl Extra (Annual)$-1.26
Current Ratio (Annual)7.37x
Quick Ratio (Quarterly)19.29x
3-Month Avg Trading Volume0.30M
52-Week Price Return-82.46%
EV / Free Cash Flow (Annual)95.61x
Revenue / Employee (TTM)$123,100
Tangible BV / Share (Quarterly)$0.53
P/S Ratio (Annual)176.46x
Asset Turnover (Annual)0.02x
52-Week High$29.16
Operating Margin (5Y Avg)-431.94%
EPS Excl Extra (Annual)$-1.26
CapEx CAGR (5Y)10.40%
Tangible BV CAGR (5Y)32.95%
26-Week Price Return-79.37%
Quick Ratio (Annual)7.26x
13-Week Price Return5.65%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)19.49x
Enterprise Value$774.82M
Revenue / Share Growth (5Y)49.17%
Asset Turnover (TTM)0.21x
Book Value / Share Growth (5Y)13.89%
Revenue / Employee (Annual)$82,200
Inventory Turnover (Annual)5.19x
Pretax Margin (Annual)-980.93%
Cash / Share (Annual)$4.48
3-Month Return Std Dev68.06%
Gross Margin (5Y Avg)-21.94%
Net Income / Employee (TTM)$-1,038,700
ROE (Last FY)-34.03%
Net Interest Coverage (Annual)-48.09x
EPS Basic Excl Extra (Annual)$-1.26
Receivables Turnover (TTM)8.26x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.64
Receivables Turnover (Annual)6.35x
ROI (TTM)-53.11%
P/S Ratio (TTM)117.90x
Pretax Margin (5Y Avg)-452.15%
Revenue / Share (Annual)$0.13
Tangible BV / Share (Annual)$0.78
Free OCF CAGR (5Y)30.87%
Price vs S&P 500 (52W)-84.50%
EPS Growth TTM (YoY)19.36%
Year-to-Date Return-7.41%
5-Day Price Return1.97%
EPS Normalized (Annual)$-1.26
ROA (5Y Avg)-46.94%
Net Profit Margin (Annual)-980.93%
Month-to-Date Return10.61%
Cash Flow / Share (TTM)$-0.78
EBITD / Share (Annual)$-1.43
Operating Margin (Annual)-1149.52%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-51.05%
LT Debt / Equity (Quarterly)62.67x
EPS Basic Excl Extra (TTM)$-1.64
P/TBV (Quarterly)1.16x
P/B Ratio (Annual)5.88x
Inventory Turnover (TTM)5.95x
Pretax Margin (TTM)-843.85%
Book Value / Share (Annual)$3.70
Price vs S&P 500 (13W)-4.09%
Beta125.39x
P/FCF (Annual)96.34x
Revenue / Share (TTM)$0.20
ROE (TTM)-47.53%
52-Week Low$14.72
gGradeB
mGradeD
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.38est. -0.34
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
4.30
4.27
4.33
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AKTSAktis Oncology, Inc. Common stock | — | B | D | $19.48 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Aktis Oncology is a clinical-stage oncology company developing targeted alpha radiopharmaceuticals for solid tumors, including breast, lung, colorectal, bladder, and liver cancers. The company focuses on expanding access to large patient populations not addressed by existing platform technologies. Its pipeline includes AKY-1189 and AKY-2519.